ERBB2 and osteosarcoma: In one patient the scan did not influence the understanding and/or treatment choice, and one physician of a patient with osteosarcoma and simultaneous HER2-positive breast cancer, rated choice of treatment based on the 89Zr-trastuzumab PET as non-beneficial for the patient, although the scan improved her understanding of the disease.